Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Injectable Aesthetics
    • Dermatological Skincare
    • Therapeutic Dermatology
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
    • The aesthetic impact of medication-driven weight loss
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Podcasts
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors

Galderma launches new Alastin Regenerating Skin Nectar with TriHex+™, powered by its next-generation TriHex Technology® regenerative platform

Press release

Interim data from two ongoing investigator-initiated trials highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause

Press release

Galderma debuts ALASTIN Signature Practices in partnership with leading aesthetic practices to elevate regenerative, peri-procedural skincare

Press release

AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis

Press release

AAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs

Press release

Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing

Press release

Galderma publishes invitation and agenda for its 2026 Annual General Meeting

Press release

AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies

Press release

Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering

Press release

Galderma completes successful placement of EUR 500 million Eurobond

Press release

Pagination

  • Next page Next Page
Subscribe to Press release
  1. Home
  2. Press release

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back